Josh Uppal

DNP Doctor of Nursing Practice,  Massachusetts General Hospital 

Location: India

Consulting Services

Journal Manuscript Sales and Marketing Case Consulting Career Advice and Mentoring

Areas Of Interest

M-Line 185 kDa Protein Cochlea radiotherapy Receptor, Ectodysplasin A2 Sodium 2-Mercaptoethanesulphonate Clinical Pathways Shoe Cover, Surgical Compound Q Spinocerebellar Ataxia-2 gamma Atrial Natriuretic Peptide Disease, Fumarylacetoacetase Deficiency Procedures, Gastroscopic Surgical Carbamoylphosphate Synthetase I Deficiency Disease Postacton Malformation, Cerebral Cavernous Physicochemical Process Plant Barks Malignant Mastocytomas Olfactory Sensory Cells Biliverdin Diagnosis, Prenatal MAP Kinase Kinase 5 Tilias Cells, Beige Brite Maxillofacial Prosthesis Physiotherapists Hyperuricemia Syndromes, Juvenile Exams, Gynecological Salaam Attacks Analogue Computer Mylohyoid Groove Consent, Presumed Immunoglobulin C2 set Domain Daily Recommended Intakes

Professional Narrative

Dr. Josh Uppal was born in DuBois, Pennsylvania and is a graduate of Villanova University. He obtained his medical degree at Thomas Jefferson University in Philadelphia. His residency was at Thomas Jefferson and its affiliated Wills Eye Hospital, and he completed his training with fellowships at the University of Connecticut incataract andcorneal surgery.

Dr. Uppal has thirty years’ experience in ophthalmic surgery,withspecialinterestin cataract surgery,corneal transplantation,andlaserrefractiveprocedures.Heisa founding member of Precision LASIK Group, Chief of Ophthalmology at The Hospital ofCentral Connecticut,andco-medical director of the Connecticut eye bank.


Employment

Senior Director, Harvard Med 1991
Senior Director, Mayo Clinic 2016

Education

Doctor of medicine, Yale School of Medicine 1994
Doctor of medicine, Yale School of Medicine 2004

Referees


Publications

Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7(5):319-34. doi: 10.4155/tde-2016-0006. Erratum in: Ther Deliv. 2016 Jun;7(6):411. PMID: 27075952; PMCID: PMC5439223.

Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z. PMID: 30622344; PMCID: PMC6410566.

Gupta A, Andresen JL, Manan RS, Langer R. Nucleic acid delivery for therapeutic applications. Adv Drug Deliv Rev. 2021 Nov;178:113834. doi: 10.1016/j.addr.2021.113834. Epub 2021 Sep 4. PMID: 34492233.

Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326-1335. doi: 10.1021/acs.nanolett.6b03329. Epub 2016 Dec 5. PMID: 28273716; PMCID: PMC5523404.


Grants,Awards and Certifications

Grants :

No Grants Mentioned !!

Awards & Prizes :


Languages

Language Proficiency :

Translation Services :